ARWR
Arrowhead Pharmaceuticals, Inc. operates as a biopharmaceutical company. It develops medicines that treat intractable diseases by silencing the genes that cause them. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.
Arrowhead Pharmaceuticals, Inc. (ARWR) is rated C (2.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B-); its weakest is Profitability (C-).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-16 | B- (2.9) | C+ (2.6) | C- (2.0) | C- (2.1) | C (2.4) | C (2.4) |
| 2026-11-09 | B- (2.9) | C (2.2) | C+ (2.6) | C (2.3) | C (2.4) | C (2.5) |
| 2026-11-02 | B- (2.9) | C (2.2) | C+ (2.7) | C (2.4) | C (2.4) | C+ (2.5) |
| 2026-10-26 | B- (3.0) | C (2.2) | C+ (2.7) | C (2.3) | C+ (2.8) | C+ (2.6) |
| 2026-10-19 | B- (3.0) | C (2.2) | C+ (2.7) | C+ (2.5) | B- (2.9) | C+ (2.7) |